Effect of, OAT3, on the Renal Secretion of Cefotaxime

• Status: Completed
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In the proposed study, we plan to use a genotype to phenotype strategy to study the role of the organic anion transporter, OAT3, in drug response. More specifically we will examine the contribution of OAT3 to the renal clearance of anionic drugs such as cefotaxime by studying individuals with a non-functional (or poorly-functional) variant of OAT3.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Francisco
• Treatments: Cefotaxime; Cefoxitin

Criteria

Inclusion Criteria:

1. Previous participation in the "SOPHIE" study;

2. Has a specific genotype for OAT3

Exclusion Criteria:

1. Under 18 years old or over 45 years old;

2. Pregnant (pregnancy status in female subjects will be determined by a urine pregnancy test before study drug administration);

3. They report a prior history of any allergic reaction to cephalosporin antibiotic, or severe hypersensitivity to penicillin;

4. Has a prior history of renal or hepatic dysfunction (renal and hepatic function will also be determined for each subject with prescreening blood tests);

5. Taking a medication that could confound study results (such as known substrates or inhibitors of OATs);

6. They do not consent to participate in the study.